Bleeding From Teeth

2
Pipeline Programs
1
Companies
1
Clinical Trials
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
1
Early DiscoveryClinical DevelopmentMarket

On Market (1)

Approved therapies currently available

U
LYSTEDAApproved
tranexamic acid
Unknown Company
Antifibrinolytic Agent [EPC]oral2009

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Hyloris Pharmaceuticals
Hyloris PharmaceuticalsBelgium - Liège
1 program
1
Tranexamic acidPhase 31 trial
Active Trials
NCT06143787Unknown280Est. Dec 2024

Trial Timeline

Clinical trial activity over time

2023
2024
2025
2026
Hyloris PharmaceuticalsTranexamic acid

Clinical Trials (1)

Total enrollment: 280 patients across 1 trials

Effect of TXA Oral Sol 5% in Patients Treated With DOACs or VKA and Undergoing a Single or Multiple Tooth Extraction

Start: Nov 2023Est. completion: Dec 2024280 patients
Phase 3Unknown

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
1 companies competing in this space